Biofrontera (BFRI) Operating Expenses (2020 - 2025)

Biofrontera's Operating Expenses history runs 6 years deep, the most recent figure standing at $12.5 million for Q4 2025.

• On a quarterly basis, Operating Expenses fell 12.12% year-over-year to $12.5 million in Q4 2025; TTM through Dec 2025 was $53.1 million, a 2.72% decrease from a year earlier, with the FY2025 full-year figure at $53.1 million, down 2.71% from the prior year.
• Operating Expenses fell to $12.5 million in Q4 2025 per BFRI's latest filing, from $13.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $20.4 million in Q3 2021 and bottomed at $8.0 million in Q3 2022.
• The 5-year median for Operating Expenses is $13.3 million (2024), against an average of $13.0 million.
• Across the five-year window, Operating Expenses surged 265.24% in 2021 and sank 61.05% in 2022, its largest moves.
• Year by year, Operating Expenses stood at $11.0 million in 2021, then soared by 42.69% to $15.8 million in 2022, then decreased by 8.27% to $14.5 million in 2023, then decreased by 1.31% to $14.3 million in 2024, then dropped by 12.12% to $12.5 million in 2025.
• Per Business Quant, the three latest BFRI Operating Expenses figures stand at $12.5 million (Q4 2025), $13.3 million (Q3 2025), and $14.1 million (Q2 2025).